Theravance Biopharma (TBPH) Income from Continuing Operations (2013 - 2026)
Theravance Biopharma (TBPH) reported Income from Continuing Operations of 4970000.0 for Q1 2026, up 63.4% year-over-year from 3041627.46 in Q1 2025, and up 91.56% quarter-over-quarter from 58893000.0 in Q4 2025.
Theravance Biopharma (TBPH) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of Income from Continuing Operations data on file, last reported at 4970000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 4970000.0, up 63.4% year-over-year; the trailing twelve-month figure through Mar 2026 was 5417000.0 (up 71.9% YoY), and the FY2025 annual result was 14014000.0, up 19.29% from the prior year.
- Income from Continuing Operations rose to 4970000.0 in Q1 2026 per TBPH's latest filing, from 58893000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 54835000.0 in Q2 2025 and troughed at 58893000.0 in Q4 2025.
- A 5-year average of 10844235.29 and a median of 13579000.0 in 2025 frame the typical range for Income from Continuing Operations.
- On a YoY basis, Income from Continuing Operations climbed as much as 431.75% in 2025 and fell as far as 350.31% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 14256000.0 in 2022, then soared by 40.47% to 8486000.0 in 2023, then jumped by 377.26% to 23528000.0 in 2024, then tumbled by 350.31% to 58893000.0 in 2025, then jumped by 91.56% to 4970000.0 in 2026.
- Business Quant data shows TBPH's Income from Continuing Operations at 4970000.0 in Q1 2026, 58893000.0 in Q4 2025, and 3611000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | -4.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.97 Mn |
| Dec 31, 2025 | -58.89 Mn |
| Sep 30, 2025 | 3.61 Mn |
| Jun 30, 2025 | 54.84 Mn |
| Mar 31, 2025 | -13.58 Mn |
| Dec 31, 2024 | 23.53 Mn |
| Sep 30, 2024 | -12.70 Mn |
| Jun 30, 2024 | -16.53 Mn |
| Mar 31, 2024 | -11.66 Mn |
| Dec 31, 2023 | -8.49 Mn |
| Sep 30, 2023 | -8.95 Mn |
| Jun 30, 2023 | -15.65 Mn |
| Mar 31, 2023 | -22.09 Mn |
| Dec 31, 2022 | -14.26 Mn |
| Sep 30, 2022 | -15.52 Mn |
| Jun 30, 2022 | -22.79 Mn |
| Mar 31, 2022 | -40.26 Mn |
| Dec 31, 2021 | -57.82 Mn |
| Sep 30, 2021 | -55.91 Mn |
| Jun 30, 2021 | -52.41 Mn |